Charles E Mowbray

List of Publications by Year
in descending order

43	1,873	304743 22	265206 42
papers	citations	h-index	g-index

48	48	48	2818
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nature Reviews Drug Discovery, 2015, 14, 751-758.	46.4	437
2	Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives. Clinical Microbiology Reviews, 2018, 31, .	13.6	145
3	Concise Synthesis of Enantiomerically Pure Phenylalanine, Homophenylalanine, and Bishomophenylalanine Derivatives Using Organozinc Chemistry:â€‰ NMR Studies of Amino Acid-Derived Organozinc Reagents. Journal of Organic Chemistry, 1998, 63, 7875-7884.	3.2	106
4	Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5857-5860.	2.2	95
5	The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Nature Communications, 2022, 13, 719.	12.8	86
6	Treatment options for second-stage gambiense human African trypanosomiasis. Expert Review of Anti-Infective Therapy, 2014, 12, 1407-1417.	4.4	84
7	Drug Discovery for Kinetoplastid Diseases: Future Directions. ACS Infectious Diseases, 2019, 5, 152-157.	3.8	78
8	Structureâ^'Activity Relationships of 1,4-Dihydro-(1H,4H)-quinoxaline-2,3-diones as N-Methyl-d-aspartate (Glycine Site) Receptor Antagonists. 1. Heterocyclic Substituted 5-Alkyl Derivatives. Journal of Medicinal Chemistry, 2001, 44, 1951-1962.	6.4	77
9	Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 11, 106-117.	3.4	58
10	Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy, 2010, 54, 4451-4463.	3.2	56
11	Polycycle construction via cascade radical fragmentation transannulation-cyclisation processes. Tetrahedron Letters, 1993, 34, 127-130.	1.4	53
12	Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity. Journal of Medicinal Chemistry, 2015, 58, 9615-9624.	6.4	52
13	Novel Indazole Non-Nucleoside Reverse Transcriptase Inhibitors Using Molecular Hybridization Based on Crystallographic Overlays. Journal of Medicinal Chemistry, 2009, 52, 1219-1223.	6.4	49
14	The role of modern drug discovery in the fight against neglected and tropical diseases. MedChemComm, 2014, 5, 688.	3.4	44
15	Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 11, 129-138.	3.4	44
16	In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 81-86.	3.4	38
17	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: A novel histamine H4 receptor antagonist. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6596-6602.	2.2	32
18	DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2021, 64, 16159-16176.	6.4	31

#	Article	IF	Citations
19	Pyrazole NNRTIs 1: Design and initial optimisation of a novel template. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5599-5602.	2.2	29
20	Pyrazole NNRTIs 3: Optimisation of physicochemical properties. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5603-5606.	2.2	29
21	Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	25
22	Comparison of the Nonâ€Nucleoside Reverse Transcriptase Inhibitor Lersivirine with its Pyrazole and Imidazole Isomers. Chemical Biology and Drug Design, 2011, 77, 393-397.	3.2	22
23	Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 207-213.	2.2	22
24	A Concise and Selective Synthesis of Novel 5-Aryloxyimidazole NNRTIs. Organic Letters, 2006, 8, 1725-1727.	4.6	17
25	Small, non-peptide C5a receptor antagonists: Part 1. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5601-5604.	2.2	17
26	Collaborative virtual screening to elaborate an imidazo[1,2-a]pyridine hit series for visceral leishmaniasis. RSC Medicinal Chemistry, 2021, 12, 384-393.	3.9	17
27	Synthesis of novel histamine H4 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1156-1159.	2.2	16
28	Optimization of 5-Aryloxyimidazole Non-Nucleoside Reverse Transcriptase Inhibitors. ChemMedChem, 2008, 3, 1756-1762.	3.2	13
29	Discovery of a small molecule inhibitor through interference with the gp120â€“CD4 interaction. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5246-5249.	2.2	11
30	Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis. Pharmaceutics, 2021, 13, 516.	4.5	11
31	A Concise Synthesis of Trifluoromethyl-Substituted 4-Aryloxy Pyrazoles. Synlett, 2006, 2006, 1404-1406.	1.8	8
32	Small, non-peptide C5a receptor antagonists: Part 2. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5605-5608.	2.2	8
33	2-aminobenzimidazoles for leishmaniasis: From initial hit discovery to in vivo profiling. PLoS Neglected Tropical Diseases, 2021, 15, e0009196.	3.0	8
34	Identification of Resistance Determinants for a Promising Antileishmanial Oxaborole Series. Microorganisms, 2021, 9, 1408.	3.6	8
35	Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2. EBioMedicine, 2022, 82, 104148.	6.1	8
36	Chapter 2. Anti-leishmanial Drug Discovery: Past, Present and Future Perspectives. RSC Drug Discovery Series, 2017, , 24-36.	0.3	7

#	Article	IF	Citations
37	Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structureâ€“activity relationship (SAR). Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6591-6595.	2.2	6
38	Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126779.	2.2	6
39	The discovery and profile of PF-0868087, a CNS-sparing histamine H3 receptor antagonist for the treatment of allergic rhinitis. MedChemComm, 2012, 3, 339-343.	3.4	5
40	Hit-to-lead optimization of a benzene sulfonamide series for potential antileishmanial agents. RSC Medicinal Chemistry, 2020, 11, 1267-1274.	3.9	5
41	Synthesis of some semi-synthetic nemadectins. Journal of the Chemical Society Perkin Transactions 1, 1990, , 1813.	0.9	4
42	Title is missing!. Journal of Chemical Crystallography, 1999, 29, 335-341.	1.1	4
43	Introduction to the themed collection on â€˜Neglected tropical diseasesâ€™. RSC Medicinal Chemistry, 2020, 11, 1098-1099.	3.9	2